// App-Quantinova.ai

9001 : Epidermal growth factor receptor (EGFR) genotyping of matched urine, plasma and tumor tissue from non-small cell lung cancer (NSCLC) patients (pts) treated with rociletinib.

Researchers

Presenter

  • Heather A. Wakelee

Principal Investigators

  • Jonathan Wade Goldman

  • Karen L. Reckamp

  • Chris Alan Karlovich

  • Vladislava Melnikova

  • Jean-Charles Soria

  • Helena Alexandra Yu

  • Benjamin J. Solomon

  • Maurice Perol

  • Joel W. Neal

  • Stephen V. Liu

  • Mitch Raponi

  • Darrin Despain

  • Mark G. Erlander

  • Shannon L. Matheny

  • Sergey Yurasov

  • D. Ross Camidge

  • Lecia V. Sequist

Medical Centers

  • Stanford Univeresity Medical Center, Stanford, CA

  • Barbara Ann Karmanos Cancer Institute, Detroit, MI

  • UCLA Medical Center, Santa Monica, CA

  • City of Hope Comprehensive Cancer Center, Monrovia, CA

  • Clovis Oncology, Inc., Boulder, CO

  • Tocagen, Inc., San Diego, CA

  • Gustave Roussy Cancer Campus, Villejuif, France

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Peter MacCallum Cancer Centre, East Melbourne, Australia

  • Hospices Civils de Lyon, Lyon, France

  • Georgetown University Medical Center, Washington, DC

  • University of Colorado Cancer Center, Aurora, CO

  • Massachusetts General Hospital, Boston, MA

Locations

  • United States

  • France

  • Australia

Companies

  • Clovis Oncology, Inc

  • TrovaGene, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non Small Cell Lung cancer

Biomarkers

  • Epidermal growth factor

  • Epidermal growth factor receptor

Drug/Treatment

  • rociletinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I/II

Study Id's

  • NCT01526928500

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved